

FOR IMMEDIATE RELEASE

CONTACT:

Michele Rozen
Pure Communications
617-730-8284

Catabasis Pharmaceuticals to Present at Upcoming Investor and Industry Conferences

CAMBRIDGE, Mass. – March 28, 2012 – [Catabasis Pharmaceuticals](#), a biopharmaceutical company leveraging the therapeutic potential of omega-3 fatty acids for the treatment of inflammatory and metabolic diseases, today announced that Michael Jirousek, Ph.D., chief scientific officer and co-founder of Catabasis, will present at the following upcoming industry conferences.

- [Needham & Company's 11th Annual Healthcare Conference](#), being held April 3-4 at the New York Palace Hotel in New York City. Dr. Jirousek will give a company presentation at 3:40 p.m. on Tuesday, April 3. This conference is a high-impact forum for institutional investors and venture capital firms to hear the latest updates from senior management teams of both public and private companies in sectors such as biotechnology, specialty pharmaceuticals, diagnostics and medical technology.
- [2nd Diabetes Summit](#), being held April 19-20 at the Hyatt Harborside in Boston. Dr. Jirousek will present an overview of CAT-1004 as a novel new chemical entity for treating type 2 diabetes in the session "Clinical Drug Development in Diabetes" at 4:05 p.m. on Thursday, April 19. This conference will bring together the leading experts on diabetes from both industry and academia to discuss novel targets for diabetes, lessons to learn from current clinical drug development, and business strategies and opportunities under the current regulatory landscape.
- [Future Leaders in the Biotech Industry](#), being held April 20 at the Millennium Broadway Hotel & Conference Center in New York City. Dr. Jirousek will give a presentation on Catabasis' novel approach to drug development at 3 p.m. The presentation will feature an overview of the company, proprietary chemistry platform and promising pipeline, including CAT-1004. This conference will showcase companies best positioned to provide market leadership and will continue to emphasize fresh investment opportunities.

About Catabasis

Catabasis is a clinical-stage company dedicated to the discovery and development of innovative, effective and safe medicines to treat inflammatory and metabolic diseases. The company has assembled a team of passionate and experienced scientists who are committed to improving the lives of patients. Catabasis has developed a pipeline of molecules that produce mechanistic synergy on a targeted pathway. The company's technology platform utilizes pathway pharmacology and has

produced a robust pipeline of new chemical entities. Catabasis' approach dramatically enhances the therapeutic potential of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), by improving their delivery, potency and efficacy through SMART linker technology. Founded in 2008, Catabasis is headquartered in Cambridge, Mass. Please visit www.catabasispharma.com for more information.

###